Skip to main content

Study Debunks Notion That Antidepressant, Fluvoxamine, Might Ease COVID Symptoms

Medically reviewed by Drugs.com.

By Cara Murez HealthDay Reporter

MONDAY, Sept. 18, 2023 -- A clinical trial designed to test repurposed medications for their impact on fighting COVID-19 has found no benefit to taking the antidepressant fluvoxamine (Luvox) to ease coronavirus symptoms.

The study, led by Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University, found no symptom improvement in those taking the antidepressant at a dose of 100 milligrams (mg) twice daily for 13 days compared to those taking a placebo.

“There was no evidence of improvement in the rate of sustained recovery in participants who took this dose of fluvoxamine versus those who took a placebo,” said researcher Dr. Adrian Hernandez, executive director of the Durham, N.C.-based institute.

Researchers studied fluvoxamine because previous evidence suggested that it might be able to reduce inflammation caused by the virus.

After finding no benefit in taking 50 mg of fluvoxamine twice daily for 10 days, the team tested the higher dose, given that it had a favorable safety profile and efficacy in other studies.

"We are testing repurposed drugs to understand if they are effective in treating COVID-19,” explained Dr. Susanna Naggie, the DCRI principal investigator overseeing the study’s clinical coordinating center. The repurposed medications in this study are already approved by the U.S. Food and Drug Administration to treat other conditions.

Fluvoxamine is one of four FDA-approved repurposed medications being tested in the new trial. It's a selective serotonin reuptake inhibitor (SSRI) used to treat obsessive-compulsive disorder and depression.

The findings appear on medRxiv, a pre-publication server. They have been submitted to a peer-reviewed journal. Findings are considered preliminary until published in a peer-reviewed journal.

The clinical trial received funding from the National Institutes of Health.

Sources

  • Duke Clinical Research Institute, news release, Sept. 14, 2023

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted September 2023

Further Support and Information on COVID-19

Read this next

Almost 1 in 3 Americans Know Someone Who's Died From a Drug Overdose

FRIDAY, May 31, 2024 -- As the opioid addiction crisis continues to lay waste to American life, a new survey finds that nearly a third of U.S. adults now know someone who's died...

Amsterdam's 'Psychiatric Ambulance' Could Be Advance For Those in Mental Health Crisis

FRIDAY, May 31, 2024 -- Ambulances meant for people having a mental health crisis could help folks get the care they need with less confrontation and friction, a new study...

Suicidal Impulses May Peak During Restless Nights

FRIDAY, May 31, 2024 -- The wee hours of the morning could be the most dangerous for someone on the brink of suicide or homicide, a new study shows. There’s a five-fold...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.